Femasys (NASDAQ:FEMY) Given New $15.00 Price Target at HC Wainwright

Femasys (NASDAQ:FEMY) had its price target upped by HC Wainwright from $12.00 to $15.00 in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Femasys Price Performance

Femasys stock opened at $1.57 on Wednesday. Femasys has a 12-month low of $0.86 and a 12-month high of $1.88. The stock has a market capitalization of $35.95 million, a P/E ratio of -1.94 and a beta of -2.85. The firm’s 50-day moving average is $1.35 and its two-hundred day moving average is $1.21. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Institutional Investors Weigh In On Femasys

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Femasys during the 4th quarter worth about $25,000. Jane Street Group LLC acquired a new stake in shares of Femasys during the 4th quarter worth about $30,000. XTX Topco Ltd boosted its position in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Femasys in the fourth quarter worth approximately $45,000. Finally, Northern Trust Corp boosted its position in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.